Alcea Tx develops monoclonal antibodies that restore immune tolerance by targeting dysregulated regulatory T-cells to treat chronic airway inflammation associated with asthma and other respiratory diseases. This approach aims to prevent acute attacks and reduce inflammation without the side effects commonly seen with existing therapies.

The startup develops radiopharmaceuticals that utilize proprietary imaging and therapeutic molecules to enhance the diagnosis and treatment of metastatic cancer. By targeting both solid and hematologic malignancies, the company provides healthcare professionals with differentiated treatment options that aim to extend patient survival while maintaining favorable safety profiles.

Alterome Therapeutics, Inc. develops alteration-specific small molecule therapies using a structure-guided machine learning platform to target validated oncogenic drivers in cancer patients with limited treatment options. The company aims to provide precise therapeutic solutions that improve patient outcomes and inspire hope in the fight against cancer.

Ansel Health provides supplemental health insurance designed to ease the financial burden of unexpected medical expenses. Their plans cover over 13,000 injuries and illnesses with customizable benefit tiers for moderate, severe, and catastrophic conditions. The platform facilitates rapid claims processing, often paying benefits within 72 hours via digital payment methods, alongside paperless administration for employers.

Ascend specializes in the manufacturing of adeno-associated virus (AAV) gene therapies, providing tailored support throughout the pre-clinical and clinical development stages. The company addresses the need for scalable and efficient production processes, enabling partners to deliver life-changing therapies to patients more quickly and affordably.

ASTRA Therapeutics develops targeted therapeutics using advanced biopharmaceutical techniques to address unmet medical needs in disease treatment. The company focuses on leveraging proprietary drug delivery systems to enhance the efficacy and safety of medications for patients with complex health conditions.

Aviceda Therapeutics is developing targeted ligands that modulate inflammation by selectively interacting with specific immune cells to treat glyco-immune diseases. This approach aims to enhance therapeutic efficacy while minimizing off-target effects in patients suffering from these conditions.

Base5 Genomics develops an immunogenomic platform that provides patient-specific genomic references to enhance precision medicine. This technology addresses the limitations of standard genomic workflows by delivering contextualized biological ground truth for clinically significant regions of the human genome.

Bonum Therapeutics develops a novel class of regulated protein therapeutics using an antibody-based mechanism for targeted drug delivery. These therapeutics remain inactive until bound to a specific target, activating potent biological activity only where needed. The company is currently focused on developing antibody-controlled cytokine-based therapeutics for cancer treatment.

CandidPro provides a clear aligner treatment platform that utilizes telehealth technology for remote monitoring and progress tracking, allowing dental professionals to oversee patient care efficiently. The service addresses misalignment issues that can lead to oral health complications by offering a tailored treatment plan that includes a full set of aligners and at-home support.

Cardurion is developing therapeutics targeting PDE9 and CaMKII pathways to treat heart failure and various cardiovascular diseases. Their approach aims to provide effective treatment options for chronic heart failure and rare arrhythmias, addressing significant unmet medical needs in cardiovascular care.

Celestial develops mRNA vaccines and therapeutics for infectious diseases and cancer. Their technology aims to provide novel preventative and treatment options through advanced mRNA delivery.

Code Ocean is a computational research platform that enables researchers to create reproducible environments and manage data through automated Dockerfile generation and integrated ML workflows. It addresses the challenges of slow collaboration and inconsistent result reproduction across diverse compute environments in computational science and bioinformatics.

Decoy Therapeutics engineers next-generation peptide conjugate therapeutics using its proprietary IMP 3 ACT™ platform. This computational approach rapidly designs drug candidates, optimizing for affinity, pharmacokinetics, and scalable manufacturing. The company focuses on developing broad-acting antivirals for respiratory viruses and targeted peptide-drug conjugates for colorectal cancers.

This startup produces animal-free dairy milk using precision fermentation to replicate the proteins and nutrients found in traditional cow's milk. Their products are vegan-friendly and lactose-free, providing a sustainable alternative that reduces the environmental impact of dairy farming.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

Elemental Machines offers a LabOps connectivity platform that combines purpose‑built IoT sensors, cloud‑native software, and AI‑driven analytics to continuously monitor equipment, environmental conditions, and workflow metrics in life‑science labs and manufacturing facilities. The platform provides real‑time, context‑sensitive alerts, interactive floorplan visualizations, and 21 CFR Part 11‑compliant audit trails, enabling proactive maintenance, optimized equipment utilization, and streamlined regulatory compliance.

EpiBiologics develops bispecific antibodies using its EpiTAC platform to selectively degrade disease-causing extracellular proteins, targeting the 40% of the proteome that intracellular methods overlook. This approach aims to enhance therapeutic efficacy for cancer and autoimmune disorders while minimizing damage to healthy tissues.

Faeth Therapeutics utilizes computational biology and machine learning to develop multi-nodal nutritional treatments that target cancer metabolism, inhibiting cell growth through a comprehensive understanding of metabolic pathways. This approach addresses the limitations of traditional therapies by expanding the range of druggable targets within the cancer metabolism landscape.

Galatea Bio designs and executes projects leveraging human genetic diversity for biomedical problem-solving. The company offers clinical testing services through a CLIA-CMS certified molecular diagnostics laboratory and biobank infrastructure. They partner with life sciences organizations to build large-scale population sequencing programs utilizing an extensive genomic-phenotypic data lake.

Gallant Therapeutics develops mesenchymal stem cell therapies to treat inflammatory and immune-mediated diseases in pets, targeting the underlying causes rather than just symptoms. Their approach aims to restore healthy tissue and improve mobility, offering new treatment options for conditions like feline chronic gingivostomatitis.

GRO Biosciences has developed a synthetic biology platform that utilizes non-standard amino acids (NSAAs) to enhance protein therapeutics, improving their potency, stability, and immunogenicity. The platform specifically targets the limitations of traditional protein therapies, enabling more effective treatments for autoimmune diseases.

Helm provides a Dynamic Copay Platform that enables TPAs and carriers to implement value-driven benefit designs for health plan members. The platform utilizes upfront pricing to encourage member engagement and informed decision-making regarding healthcare utilization. It facilitates smart claim bundling to offer members guaranteed prices while maintaining standard provider fee-for-service reimbursement.

Judo Bio develops oligonucleotide medicines that utilize its STRIKE platform to enable receptor-mediated uptake of siRNA specifically in kidney cells. The company's megalin-STRIKER programs target solute carrier proteins to reduce the accumulation of circulating solutes associated with systemic and renal diseases.